Glutamate AMPA receptor antagonist treatment for ischaemic stroke

Current Medical Research and Opinion

Volumn 18, Issue SUPPL. 2, 2002, Pages s9-s13

  Akins, Paul T ^a   Atkinson, Richard P ^b  

^a Regional Stroke Intervention Program   (United States)

^b NONE   (United States)

Author keywords

AMPA receptor; Excitotoxicity; Ischaemic stroke; Neuroprotection

Indexed keywords

AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; GLUTAMIC ACID;

ANIMAL; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG ANTAGONISM; HUMAN;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; RECEPTORS, AMPA;

EID: 0036362716     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/030079902125000660     Document Type: Article

References (22)

1. Johnson EM Jr, Greenlund LJS, Akins PT, Hsu CY. Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. J Neurotrauma 1995;12:843-52
2. Choi DC, Lobner D, Dugan LL. Glutamate receptor-mediated neuronal death in the ischemic brain. In Hsu CY, ed. Ischemic Stroke: from Basic Mechanisms to New Drug Development. Monographs in Clinical Neuroscience Vol 16. Basel: Karger, 2-13
3. Waxman SG, Ransom BR. Hypoxic/ischemic injury of white matter. In Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease: Pathophysiology, Diagnosis, and Management. Malden, Massachusetts: Blackwell Science, 1998;157-75
4. McDonald JW, Althomsons SP, Hyrc KL, et al. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998;4:291-7
5. Sheardown MJ, Nielsen EO, Hansen AJ, et al. 2, 3-dihydroxy-6-nitro-7- sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990;247: 571-4
6. Buchan AM, Xue D, Huang ZG, et al. Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia. Neuroreport 1991;2:473-6
7. Gill R, Nordholm L, Lodge D. The neuroprotective actions of 2, 3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxa-line (NBQX) in a rat focal ischemia model. Brain Res 1992; 580:35-43
8. Graham SH, Chen J, Lan JQ, Simon RP. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia. J Pharmacol Exp Ther 1996;276:1-4
9. Kanellopoulos GK, Xu XM, Hsu CY, et al. White matter injury in spinal cord ischemia: protection by AMPA/kainate glutamate receptor antagonism. Stroke 2000;31:1945-52
10. Wrathall JR, Choiniere D, Teng YD. Dose-dependent reduction of tissue loss and functional impairment after spinal cord trauma with the AMPA/kainate antagonist NBQX. J Neurosci 1994;14:6598-607
11. Kohara A, Okada M, Tsutsumi R, et al. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5- methylisoxazole-4-pro-pionate receptor antagonist. J Pharm Pharmacol 1998;50: 795-801
12. Takahashi M, Ni JW, Kawasaki-Yatsugi S, et al. YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats. J Pharmacol Exp Ther 1998;284:467-73
13. Haberg A, Takahashi M, Yamaguchi T, et al. Neuro-protective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion. Brain Res 1998;811:63-70
14. Kawasaki-Yatsugi S, Yatsugi S, Takahashi M, et al. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Res 1998;793:39-46
15. Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, et al. Neuro-protective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model. Neuropharmacology 2000;39:211-17
16. Ni JW, Takahashi M, Yatsugi S, et al. Effects of YM872 on atrophy of substantia nigra reticulata after focal ischemia in rats. Neuroreport 1998;9:3719-24
17. Shimizu-Sasamata M, Kano T, Rogowska J. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Stroke 1998;29:2141-8
18. Takahashi M, Ni JW, Kawasaki-Yatsugi S, et al. Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats. J Pharmacol Exp Ther 1998;287:559-66
19. Edwards D, and the CNS-1102-008 Study Group. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: results of a phase II trial. Neurology 1996;46:A424 (Abstr)
20. Davis SM, Lees KR, Albers GW, et al. ASSIST investigators. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 2000;31:347-54
21. Van Hoogdalem E, de Vos R, Hefting NR, Napoliello MJ. Clinical experience with YM872, a novel AMPA receptor antagonist for acute ischemic stroke. Stroke 1999;30:264 (Abstr)
22. Buchan AM, Lesiuk H, Barnes KA, et al. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke 1993;24 (Suppl):I148-52